Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - cyproterone acetate, quantity: 2 mg; ethinylestradiol, quantity: 35 microgram - tablet - excipient ingredients: microcrystalline cellulose; magnesium stearate; lactose monohydrate - indicated for the treatment of signs of androgenisation in women such as severe acne (involving inflammation or nordularity or risk of scarring) where prolonged oral antibiotics or local treatment alone has not been successful, or idiopathic hirsutism of mild to moderate degree. tyra-35ed will also provide effective oral contraception in this patient group. if the hirsutism has only recently appeared or has lately intensified to a considerable extent, the cause (androgen-producing tumour or an adrenal enzyme defect) must be clarified by differential diagnosis.

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - cyproterone acetate, quantity: 2 mg; ethinylestradiol, quantity: 35 microgram - tablet - excipient ingredients: microcrystalline cellulose; magnesium stearate; lactose monohydrate - indicated for the treatment of signs of androgenisation in women such as severe acne (involving inflammation or nordularity or risk of scarring) where prolonged oral antibiotics or local treatment alone has not been successful, or idiopathic hirsutism of mild to moderate degree. danica-35ed will also provide effective oral contraception in this patient group. if the hirsutism has only recently appeared or has lately intensified to a considerable extent, the cause (androgen-producing tumour or an adrenal enzyme defect) must be clarified by differential diagnosis.

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - cyproterone acetate, quantity: 2 mg; ethinylestradiol, quantity: 35 microgram - tablet - excipient ingredients: microcrystalline cellulose; magnesium stearate; lactose monohydrate - indicated for the treatment of signs of androgenisation in women such as severe acne (involving inflammation or nordularity or risk of scarring) where prolonged oral antibiotics or local treatment alone has not been successful, or idiopathic hirsutism of mild to moderate degree. ava-35ed will also provide effective oral contraception in this patient group. if the hirsutism has only recently appeared or has lately intensified to a considerable extent, the cause (androgen-producing tumour or an adrenal enzyme defect) must be clarified by differential diagnosis.

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - cyproterone acetate, quantity: 2 mg; ethinylestradiol, quantity: 35 microgram - tablet - excipient ingredients: microcrystalline cellulose; magnesium stearate; lactose monohydrate - indicated for the treatment of signs of androgenisation in women such as severe acne (involving inflammation or nordularity or risk of scarring) where prolonged oral antibiotics or local treatment alone has not been successful, or idiopathic hirsutism of mild to moderate degree. amelia-35ed will also provide effective oral contraception in this patient group. if the hirsutism has only recently appeared or has lately intensified to a considerable extent, the cause (androgen-producing tumour or an adrenal enzyme defect) must be clarified by differential diagnosis.

Canada - English - Health Canada

sun pharma canada inc - cyproterone acetate; ethinyl estradiol - tablet - 2mg; 0.035mg - cyproterone acetate 2mg; ethinyl estradiol 0.035mg - other miscellaneous therapeutic agents

Canada - English - Health Canada

teva canada limited - cyproterone acetate; ethinyl estradiol - tablet - 2mg; 0.035mg - cyproterone acetate 2mg; ethinyl estradiol 0.035mg - other miscellaneous therapeutic agents

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - cyproterone acetate -

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - cyproterone acetate, quantity: 2 mg; ethinylestradiol, quantity: 35 microgram - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; magnesium stearate - indicated for the treatment of signs of androgenisation in women such as severe acne (involving inflammation or nordularity or risk of scarring) where prolonged oral antibiotics or local treatment alone has not been successful, or idiopathic hirsutism of mild to moderate degree.,estelle-35ed will also provide effective oral contraception in this patient group. it should not be used in combination with other hormonal contraceptives (see contraindications),if the hirsutism has only recently appeared or has lately intensified to a considerable extent, the cause (androgen-producing tumour or an adrenal enzyme defect) must be clarified by differential diagnosis.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - cyproterone acetate, quantity: 2 mg; ethinylestradiol, quantity: 35 microgram - tablet, sugar coated - excipient ingredients: macrogol 6000; lactose monohydrate; sucrose; povidone; purified talc; calcium carbonate; glycol montanate; maize starch; magnesium stearate - juliet-35 ed is indicated for: the treatment of signs of androgenisation in women, such as severe acne (involving inflammation or nodularity or risk of scarring) where prolonged oral antibiotics or local treatment alone has not been successful, or idiopathic hirsutism of mild to moderate degree. juliet-35 will also provide effective oral contraception in this patient group. it should not be used in combination with other hormonal contraceptives (see contraindications).,if the hirsutism has only recently appeared or has lately intensified to a considerable extent the cause (androgen-producing tumour or an adrenal-enzyme defect) must be clarified by differential diagnosis. the treatment of signs of androgenisation in women such as severe acne (involving inflammation or nodularity or risk of scarring) where prolonged oral antibiotics or local treatment alone has not been successful, or idiopathic hirsutism of mild to moderate degree. juliet-35 ed will also provide effective oral contraception in this patient group. if the hirsutism has only recently appeared or has lately intensified to a considerable extent the cause (androgen-producing tumour or an adrenal-enzyme defect) must be clarified by differential diagnosis.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - cyproterone acetate, quantity: 2 mg; ethinylestradiol, quantity: 35 microgram - tablet, sugar coated - excipient ingredients: maize starch; calcium carbonate; purified talc; sucrose; glycol montanate; macrogol 6000; povidone; lactose monohydrate; magnesium stearate; glyceryl montanate - brenda-35 ed is indicated for the treatment of signs of androgenisation in women such as severe acne (involving inflammation or nodularity or risk of scarring) where prolonged oral antibiotics or local treatment alone has not been successful, or idiopathic hirsutism of mild to moderate degree.,brenda-35 ed will also provide effective oral contraception in this patient group. it should not be used in combination with other hormonal contraceptives (see contraindications).,if the hirsutism has only recently appeared or has lately intensified to a considerable extent, the cause (i.e. androgen-producing tumour or an adrenal enzyme defect) must be clarified by differential diagnosis.